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Abstract
Background: MicroRNAs (miRNAs) are non-coding RNA molecules involved in post-
transcriptional control of gene expression of a wide number of genes, including those involved in
glucose homeostasis. Type 2 diabetes (T2D) is characterized by hyperglycaemia and defects in
insulin secretion and action at target tissues. We sought to establish differences in global miRNA
expression in two insulin-target tissues from inbred rats of spontaneously diabetic and
normoglycaemic strains.
Methods: We used a miRNA microarray platform to measure global miRNA expression in two
insulin-target tissues: liver and adipose tissue from inbred rats of spontaneously diabetic (Goto-
Kakizaki [GK]) and normoglycaemic (Brown-Norway [BN]) strains which are extensively used in
genetic studies of T2D. MiRNA data were integrated with gene expression data from the same rats
to investigate how differentially expressed miRNAs affect the expression of predicted target gene
transcripts.
Results: The expression of 170 miRNAs was measured in liver and adipose tissue of GK and BN
rats. Based on a p-value for differential expression between GK and BN, the most significant change
in expression was observed for miR-125a in liver (FC = 5.61, P = 0.001, Padjusted = 0.10); this
overexpression was validated using quantitative RT-PCR (FC = 13.15, P = 0.0005). MiR-125a also
showed over-expression in the GK vs. BN analysis within adipose tissue (FC = 1.97, P = 0.078,
Padjusted = 0.99), as did the previously reported miR-29a (FC = 1.51, P = 0.05, Padjusted = 0.99). In-silico
tools assessing the biological role of predicted miR-125a target genes suggest an over-
representation of genes involved in the MAPK signaling pathway. Gene expression analysis
identified 1308 genes with significantly different expression between GK and BN rats (Padjusted <
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BMC Medical Genomics 2009, 2:54 http://www.biomedcentral.com/1755-8794/2/540.05): 233 in liver and 1075 in adipose tissue. Pathways related to glucose and lipid metabolism
were significantly over-represented among these genes. Enrichment analysis suggested that
differentially expressed genes in GK compared to BN included more predicted miR-125a target
genes than would be expected by chance in adipose tissue (FDR = 0.006 for up-regulated genes;
FDR = 0.036 for down-regulated genes) but not in liver (FDR = 0.074 for up-regulated genes; FDR
= 0.248 for down-regulated genes).
Conclusion: MiR-125a is over-expressed in liver in hyperglycaemic GK rats relative to
normoglycaemic BN rats, and our array data also suggest miR-125a is over-expressed in adipose
tissue. We demonstrate the use of in-silico tools to provide the basis for further investigation of the
potential role of miR-125a in T2D. In particular, the enrichment of predicted miR-125a target genes
among differentially expressed genes has identified likely target genes and indicates that integrating
global miRNA and mRNA expression data may give further insights into miRNA-mediated
regulation of gene expression.
Background
MicroRNAs (miRNAs) are short (~22 nucleotides) non-
coding RNA molecules that regulate gene expression at a
post-transcriptional level through sequence alignment
mechanisms. MiRNA molecules bind to the 3' untrans-
lated region (UTR) of their target mRNAs and can cause
either mRNA degradation or translational repression,
resulting in reduced protein expression [1] or transla-
tional activation depending on cell cycle stage [2]. Degra-
dation of mRNA seems to be favoured if the binding
occurs with perfect sequence complementarity and is
widely observed in plant miRNAs [3,4]. A variety of stud-
ies have demonstrated that regulation at the mRNA level
also occurs for animal miRNAs [5,6]. Microarray-based
experiments have shown that overexpression of specific
miRNAs in human cells down-regulates many transcripts
predicted to bind the miRNA molecule [6-8]. Conversely,
silencing of endogenous miR-122 in mice caused the pref-
erential up-regulation of transcripts containing miR-122
binding sites [9].
MiRNA expression levels are thought to contribute to tis-
sue-specific gene expression patterns [10] and computa-
tional approaches to integrating miRNA and gene
expression data have provided insights into miRNA-
mRNA interactions [11,12]. A single miRNA molecule can
affect the expression of many target genes and therefore
miRNAs are thought to be involved in the regulation of a
wide variety of normal biological processes [13].
Type 2 diabetes (T2D) is characterized by hyperglycaemia
that arises via combined defects in insulin secretion (beta-
cell dysfunction) and insulin action (in target tissues like
adipose tissue, liver and skeletal muscle). Specific miRNAs
involved in various aspects of glucose and lipid metabo-
lism have been identified in recent years [14,15]. In par-
ticular, using murine models, miR-9 and miR-375 are
reported to be involved in regulation of insulin secretion
[16,17], while miR-124a2 has recently been implicated in
pancreatic beta-cell development and function [18].
Despite the growing evidence that miRNAs may be impor-
tant in T2D, only one study of global miRNA expression
in insulin target tissues has been published to date. He et
al. (2007) [19] profiled miRNA expression in skeletal
muscle in the Goto-Kakizaki (GK) rat, a well-characterized
model of T2D, and compared it to normal Wistar rats;
miR-29 paralogs were found to be over-expressed in the
GK rat. The widely-studied GK rat has several features that
make it a good model for T2D as hyperglycaemia appears
as early as 2–4 weeks of age, and it is relatively lean [20].
In the present study, we aim to identify differential liver
and adipose tissue miRNA expression in rats of the GK
strain and a genetically distant normoglycaemic strain
(Brown-Norway (BN)). The GK strain is extensively used
to study genetic determinants of T2D phenotypes [21],
while the BN strain is widely used for comparison with GK
and most congenic strains with a BN background. Addi-
tionally, we assessed mRNA expression levels in the same
tissues from the same rats to investigate the downstream
effects of altered miRNA expression on target gene expres-
sion; the approach is illustrated in additional File 1 [Addi-
tional file 1].
Methods
Experimental animals
The GK rat is a lean and spontaneously type 2 diabetic ani-
mal, while the BN rat serves as a normoglycaemic control.
Four-month old rats representative of the GK and BN col-
onies have been phenotyped previously. An intra-perito-
neal glucose tolerance test (IPGTT) [22] was carried out
after a 16–18 h fasting period, and plasma glucose con-
centrations were significantly higher in GK compared to
BN rats [see Additional file 2]. The current experiments
were performed using seven-month-old male rats: four
from the GK strain and four from the BN strain, obtained
from the Oxford colony (GK/Ox and BN/Ox), and main-
tained in accordance with national and institutional
guidelines. Rats were fed standard laboratory chow pelletsPage 2 of 11
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cycles. Liver and adipose tissue samples were obtained
from the rats, snap-frozen in liquid nitrogen and stored at
-80°C. Total RNA was extracted from homogenized tissue
samples using TRI-Reagent (Sigma, UK) according to the
manufacturer's instructions for use in miRNA and mRNA
experiments (see below). Animal procedures were
approved by the ethical review panel of the University of
Oxford and UK Home Office licences.
Microarray analysis
Ambion miRNA arrays
MiRNAs were isolated and purified using mirVana miRNA
isolation kit (Ambion). Poly-A tailing was added to 400
ng of each small RNA fraction using Ncode miRNA label-
ling system (Invitrogen), which also adds the fluorescent
labels Alexa Fluor® 3 and Alexa Fluor® 5. The synthetic
sequence control-1 (Ambion) was spiked in to each BN
and GK sample in a ratio of 1:10, just before starting the
labelling. For each tissue, eight independent samples
(four GK and four BN) were combined in four two-colour
hybridisations, with one GK and one BN sample hybrid-
ized to each array. Within each tissue, half the arrays had
GK samples labelled with Alexa Fluor® 5 and the other half
had BN samples labelled with Alexa Fluor® 5.
Samples were hybridised to Ambion mirVana™ miRNA
Probe Set 1564v1 arrays for 4 h at 62°C in dark condi-
tions. The array contains 384 unique probes with 16 rep-
licates of each probe. Each probe is 42 to 46 nucleotides
(nt) long, of which an 18 to 24 nt segment targets a spe-
cific miRNA. MiRNA sequences are highly conserved
between species, and the Ambion array includes probes
for human, rat and mouse miRNAs. A total of 170 probes
on the array are able to detect rat miRNAs and these were
included in subsequent analyses. After hybridization,
arrays were washed and scanned using the GenePix 4000B
scanner (Axon Instruments [Molecular Devices]). Gene-
Pix Pro 4.0 software (Axon Instruments [Molecular
Devices]), was used to obtain raw probe intensities.
Statistical analysis of Ambion miRNA data
Raw data were imported into the R statistical package [23]
and processed using the 'marray' package from Biocon-
ductor [24]. Raw intensities were adjusted by subtracting
the background intensity from each probe, and the data
were then summarised by taking the median intensity
across the 16 replicates of each probe. Data were normal-
ized using the loess regression-based method within
arrays to correct for any intensity-dependent dye bias [25].
A between-array normalisation was not required as all
arrays showed comparable M-ratio distributions. Due to
expected tissue differences in miRNA expression, differen-
tial expression between GK and BN rats was assessed in
adipose tissue and liver samples separately. The experi-
mental design (see above) generated M-ratios (log-ratio of
red and green intensities) representing the log ratio of
expression in the two strains. The M-ratios could therefore
be used to investigate strain differences, the main objec-
tive of this study. We used the limma package from Bio-
Conductor [26] to fit a linear model (including a dye
effect) to the M-ratio data from the 4 arrays corresponding
to each tissue. This generated a list of miRNA probes
ranked by p-value for the evidence for differential expres-
sion between the GK and BN rats. Raw p-values were
adjusted using the method of Benjamini and Hochberg
[27] to control the false discovery rate (FDR). Differential
expression between liver and adipose tissue could also be
investigated using the A-ratios, which represent the aver-
age intensity (log scale) of the GK and BN samples hybrid-
ised to each array. Assuming strain differences are small in
comparison to tissue differences, the fold change (liver vs.
adipose tissue) can be estimated as the difference in mean
A-ratio between the 4 liver and 4 adipose tissue arrays.
Illumina mRNA arrays
Gene expression profiling of liver and adipose tissue sam-
ples from the same rats investigated in the miRNA experi-
ment was performed using Sentrix® BeadChip RatRef-12
v1 Whole-Genome Gene Expression Arrays (Illumina Inc.,
San Diego, California, USA), which contain 22,523 oligo-
nucleotides probes (replicated an average of 30 times).
Double-stranded cDNA and purified biotin-labelled
cRNA were synthesised from 300 ng high quality total
RNA using the Illumina® TotalPrep RNA Amplification Kit
(Ambion Inc., Austin, Texas, USA). cRNA concentrations
were determined using a NanoDrop spectrophotometer,
and cRNA quality and integrity were assessed using an
Agilent 2100 Bioanalyser (Agilent Technologies, Wald-
bronn, Germany). Hybridisations onto Sentrix® BeadChip
RatRef-12 v1 arrays were carried out using 750 ng of each
biotinylated cRNA in a 58°C hybridisation oven for 18
hours. Following washing and staining with Streptavidin-
Cy3, the BeadChip Arrays were scanned on the Illumina®
BeadArray Reader (Illumina Inc., San Diego, USA). The
quality of the resulting data was checked using the Illu-
mina® BeadStudio Application software
Statistical analysis of Illumina mRNA data
Raw intensity data were imported into the R statistical
package [23] for further processing. First, an array-specific
background measure, based on the average signal from
negative control probes, was subtracted from all probes
on the array. Data were then transformed and normalized
using the vsn2 BioConductor package [28]. Hierarchical
clustering showed samples clustered primarily according
to tissue, with GK and BN samples forming two sub-clus-
ters within the adipose tissue cluster. Differential expres-
sion between the GK and BN strains was assessed in liver
and adipose tissue samples separately using the limmaPage 3 of 11
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adjusted to control the false discovery rate (FDR) using
the method of Benjamini and Hochberg [27]; adjusted p-
values below 0.05 were considered significant.
The entire datasets (for miRNA and mRNA) described
here are available from the Gene Expression Omnibus
(GEO, http://www.ncbi.nlm.nih.gov/projects/geo/)
through series accession number GSE17060.
Quantitative real-time PCR validation methods
Quantitative real-time PCR was carried out on the remain-
der of RNA available from liver tissues using ABI's Taq-
Man microRNA assays (Applied Biosystems (ABI),
Warrington, Cheshire, UK). Briefly, reverse transcription
(RT) was carried out in a total reaction volume of 15 μl
containing 5 μl of total RNA (10 ng/ul), 3 μl of reverse
transcription primer, 1.50 μl of 10× RT buffer, 1.00 μl
MultiScribe Reverse Transcriptase (50 U/μl), 0.15 μl of
100 mM dNTPs (with dTTP), 0.19 μl of RNase Inhibitor,
20 U/μl and 4.16 μl of nuclease-free water. Reactions were
incubated as per manufacturer's recommendation. PCRs
were performed in triplicate, the 20-μL PCR reaction con-
tained: 1.33 μL RT product, 10 μL 2× PCR Master Mix, 1-
μL microRNA primer (ABI, UK) and 7.67 μl of nuclease-
free water. The reactions were incubated at 95°C for 10
min, followed by 40 cycles of 95°C for 15 s, 60°C for 35
s. The highly conserved snoRNA and 4.5S RNA(H) (rat)
were used as normalizing endogenous controls. Fold
changes (FC) in expression were calculated using the 2-
(ΔΔCt) method [29]. Stocks of adipose tissue were depleted
when used in the miRNA and mRNA studies, which did
not allow for validation using RT-PCR.
In-silico prediction of miRNA target genes
In-silico prediction of miRNA target genes was carried out
using three different prediction algorithms: TargetScan
v4.1 [30], PicTar [31] and miRanda [32]. The first two
algorithms predict binding sites preferentially based on
the 5' end of the 22 nt miRNA sequence, while miRanda
predictions are more sensitive to the sequence at the 3'
end. Each prediction algorithm generally identifies hun-
dreds of potential target genes for any single miRNA and
there is relatively little overlap between different algo-
rithms. However, TargetScan and PicTar show a higher
degree of overlap than either does with miRanda [Addi-
tional file 3], as might be expected based on the
approaches implemented by the different algorithms.
These predicted target lists may also contain a significant
proportion of false-positives i.e. the sequences align, but
no functional miRNA-mRNA interaction occurs in vivo
[33]. With little experimental data, it is difficult to deter-
mine which algorithm performs best; thus, all analyses
were performed with each list separately as well as with
the subset of target genes predicted by at least two of the
three algorithms. The latter list may be more likely to
include a higher proportion of true target genes than any
one list alone, but will be biased towards TargetScan/Pic-
Tar predictions.
In-silico functional analysis
Biological pathways defined by KEGG [34] that are
enriched among the predicted target genes of miR-125a
and the lists of differentially expressed mRNAs found in
liver and adipose tissue were identified using the GENE-
CODIS software [35]. This profiling tool uses the hyperge-
ometric distribution to determine whether individual
pathways or combinations of pathways are significantly
over-represented among the genes of interest. P-values
computed for each pathway were adjusted using the
method of Benjamini and Hochberg [36] to control the
false discovery rate (FDR) and adjusted p-values < 0.05
were considered significant.
Enrichment of miR-125a target genes among differentially 
expressed genes
Using the mRNA expression data, we investigated whether
predicted miR-125a target genes were differentially
expressed in liver or adipose tissue. Since miRNAs can
cause degradation of target mRNAs, over-expression of
miR-125a in both tissues in the GK rat may down-regulate
its target genes in GK relative to BN. As described above, 3
different algorithms were used to generate target gene lists
for miR-125a. Each of these lists, together with the subset
of 152 genes predicted by more than one algorithm, was
tested in this analysis. Only target genes present on the
array were included, which typically reduced the list of tar-
gets by about 40% (Table 1). We first calculated how
many genes in each of the four target gene lists were
among the significantly down-regulated genes in adipose
tissue (n = 598) and liver (n = 138). Then, a permutation
test was used to assess whether the observed overlap was
greater than that expected by chance. Specifically, we
selected 10,000 random sets of genes that were not pre-
dicted targets of miR-125a, with each set containing the
same number of genes as predicted targets. The overlap
with the down-regulated genes in adipose tissue and liver
was calculated for each of the 10,000 random gene sets.
The proportion of random gene sets showing equal or
greater overlap as the set of miR-125a target genes was
used to estimate the false discovery rate. This analysis was
carried out 8 times in total (for each of four lists in two tis-
sues) and repeated exactly as above for the up-regulated
genes.
Results
Differences in miRNA expression between GK and BN rats
The expression of 170 miRNAs in adipose tissue and liver
from hyperglycaemic GK and normoglycaemic BN rats
was detected using two-colour microarray technologyPage 4 of 11
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Table 1: Overlap between predicted miR-125a target genes and genes significantly altered in GK compared to BN rats in adipose 
tissue and in liver.
miRanda PicTar TargetScan >1 Algorithm
Predicted miR-125a target genes 975 350 165 152
Number genes tested 536 231 94 114
Overlap FDR Overlap FDR Overlap FDR Overlap FDR
Liver up-regulated (95 genes) 5 0.074 1 0.63 1 0.33 1 0.40
Liver down-regulated (138 genes) 5 0.248 2 0.43 0 1.00 0 1.00
Adipose up-regulated (477 genes) 21 0.006 5 0.57 1 0.87 3 0.46
Adipose down-regulated (598 genes) 22 0.036 7 0.44 1 0.92 0 1.00
The number of predicted miR-125a target genes found among the significantly up- and down-regulated genes in each tissue is shown for each 
algorithm and for the subset of targets predicted by more than one algorithm. In each case, the significance of the overlap (estimated false discovery 
rate) is calculated as the proportion of 10,000 random sets of non-miR-125 target genes of the same size showing equal or greater overlap.
Relative expression of miR-125a in liver from diabetic GK rats compared to BN ratsFigure 1
Relative expression of miR-125a in liver from diabetic GK rats compared to BN rats. * P = 0.0005 (miR-125a 
expression normalized against snoRNA and 4.5S).
BMC Medical Genomics 2009, 2:54 http://www.biomedcentral.com/1755-8794/2/54(Ambion mirVana™ miRNA Probe Set 1564v1). As
expected tissue-specific patterns of miRNA expression
were detected [Additional file 4]; all subsequent GK vs. BN
analyses were carried out within tissues. Differences in
miRNA expression across strains were ranked by p-value
from an analysis of differential expression using the
limma package [26] from BioConductor [24]. Twelve
probes in liver and four probes in adipose tissue were dif-
ferentially expressed between GK and BN rats at a nomi-
nal p < 0.05 significance level (Table 2). Following FDR
correction for multiple testing (for 170 probes) none of
these remained significant, likely due to the small sample
size (4 arrays per tissue). MiR-125a was the most signifi-
cant result for GK vs. BN in liver (FC = 5.62, P = 0.001, Pad-
justed = 0.10)), and we confirmed this over-expression of
miR-125a by RT-PCR (FC = 13.15, two-sided t-test P =
0.0005) (Figure 1). The top-ranking miRNA in adipose tis-
sue was miR-322 (FC = 1.91, P = 0.029 Padjusted = 0.99) but
it did not rank highly in the liver. MiR-29a, which ranked
fourth in the adipose GK vs. BN comparison, has been
previously reported to be over-expressed in adipose tissue
in GK rats when compared to normoglycaemic Wistar
controls [19]. The only miRNA that showed some evi-
dence of change in expression in both liver and adipose
tissue is miR-125a, which ranked top in the liver and fifth
in the GK vs. BN comparison in adipose tissue (FC = 1.97,
P = 0.078, Padjusted = 0.99).
Differences in gene (mRNA) expression between GK and 
BN rats
Gene expression levels in adipose tissue and liver from the
same rats used in the miRNA experiment were analysed
using the Illumina Rat Ref12 array. We identified 1075
genes differentially expressed (adjusted p < 0.05) in adi-
pose tissue in the hyperglycaemic GK rat compared to the
normoglycaemic BN rat (477 up-regulated and 598 down-
regulated). In liver, we found 233 differentially expressed
genes, of which 95 were up regulated in GK rats and 138
were down regulated (Figure 2). A total of 101 genes were
significantly altered in both adipose tissue and liver, with
the vast majority showing the same direction of change in
both tissues (41 up and 55 down). The robustness of gene
differential expression is supported by the previously rep-
licated array experiments using two well established and
technologically different platforms using RNA from the
current samples [37]. In-silico functional profiling of the
significant genes revealed similar results in both tissues
(Table 3), including several pathways related to glucose
lipid metabolism: prostaglandin and leukotriene metabo-
lism (Padjusted = 0.001 in adipose tissue, Padjusted = 0.002 in
liver), glycolysis/gluconeogenesis in adipose tissue (Pad-
justed = 0.003) and fatty acid metabolism in liver (Padjusted =
0.01). A number of amino acid metabolism categories
were also significant in both tissues (Table 3). (Details of
Table 2: MiRNA microarray analysis reveals differential expression between hyperglycaemic and normoglycaemic rats
Rank miRNA Fold change
(GK vs. BN)
P-value Adjusted
P-value
Liver
1 miR-125a 5.61 0.001 0.104
2 miR-30e 1.56 0.009 0.522
3 miR-210 1.56 0.013 0.522
4 miR-221 1.60 0.015 0.522
5 miR-223 1.50 0.015 0.522
6 miR-365 1.41 0.029 0.592
7 miR-26b 1.51 0.031 0.592
8 miR-23a 2.30 0.032 0.592
9 miR-222 1.38 0.033 0.592
10 miR-29c 1.52 0.038 0.592
11 miR-30a-3p 1.32 0.045 0.592
12 miR-22 -1.39 0.050 0.592
Adipose tissue
1 miR-322 1.91 0.029 0.999
2 let-7c -2.27 0.040 0.999
3 let-7b -2.17 0.046 0.999
4 miR-29a 1.51 0.049 0.999
5* miR-125a 1.97 0.078 0.999
Differences in miRNA expression levels in 4 hyperglycaemic GK rats compared to 4 normoglycaemic BN rats in liver and adipose tissue. For each 
tissue, one GK and one BN sample were hybridized to each array in a two-colour experiment (4 arrays per tissue). M-ratios therefore represent 
the log2 intensity ratio in the two strains. The limma package from BioConductor was used to find miRNAs differentially expressed between GK 
and BN rats and the top ranking genes for each tissue are shown. * miR-125a is shown in this table to illustrate the potential overlap of signals 
detected in liver and adipose tissue.Page 6 of 11
(page number not for citation purposes)
BMC Medical Genomics 2009, 2:54 http://www.biomedcentral.com/1755-8794/2/54individual genes for all significant categories are given in
[Additional file 5]).
Predicted targets for miR-125a and in-silico functional 
profiling
The miRNA target gene prediction algorithms TargetScan
4.1 [38], PicTar [31] and miRanda [32] generated target
gene lists for miR-125a comprising 165, 350 and 975
genes, respectively. Of these, 152 genes were predicted by
more than one algorithm [Additional file 3] and only 17
are predicted by all algorithms. The target gene lists were
analysed using the GENECODIS tool to investigate the
biological pathways (KEGG) that may be affected by over-
expression of miR-125a in liver and, to a lesser extent, adi-
pose tissue. When the set of 152 miR-125a target genes
was tested, mitogen-activated protein kinase (MAPK) sig-
naling was the only pathway to show significant over-rep-
resentation (Padjusted = 3 × 10-5). The MAPK signaling
pathway was also significant when each predicted target
list was analysed separately, and was the top-ranking
pathway for the lists generated by TargetScan and PicTar
[Additional file 6]. Other significant pathways of note
included insulin signaling (Padjusted = 0.03, PicTar gene list)
and, with the miRanda list, glycerolipid metabolism (Pad-
justed = 0.02) and calcium signaling (Padjusted = 0.05).
Enrichment of miR-125a target genes among differentially 
expressed genes
Given the evidence for miRNA regulation at the mRNA
level in animals [6,9,10], integration of miRNA-mRNA
expression data was also performed. Since miR-125a was
the top-ranking miRNA in liver, and fifth-ranked in adi-
pose tissue, we hypothesized that target genes of miR-
125a would be differentially expressed between GK and
BN rats in both tissues. Specifically, overexpression of
miR-125a in these tissues in the GK rat would be expected
to down-regulate miR-125a target genes [1,6,39]. Target
genes predicted by all algorithms (n = 17), plus the set of
152 genes predicted by more than one algorithm, were
tested for enrichment among the 598 genes significantly
down-regulated in GK compared to BN rats in adipose tis-
sue and among the 138 down-regulated genes in liver
(Table 1). Greater overlap than expected by chance (see
Methods) was observed in adipose tissue (overlap = 22,
FDR = 0.04) but not in liver (overlap = 5, FDR = 0.25) for
the set of 536 target genes predicted by the miRanda algo-
rithm and present on the Illumina RatRef 12 array. Three
miR-125a target genes (Slc35c2, Umps and Ptges2) were
significantly down-regulated in GK rats in both tissues.
Contrary to expectation, a significant enrichment was also
observed when the up-regulated genes were tested (over-
lap = 21, FDR = 0.006 in adipose tissue; overlap = 5, FDR
= 0.07 in liver). For both up- and down-regulated genes,
there was more overlap in adipose tissue compared to
Gene expression analysis of adipose tissue and liver reveals differential expression between hyperglycaemic and normoglycae-mic ratsFigur  2
Gene expression analysis of adipose tissue and liver reveals differential expression between hyperglycaemic 
and normoglycaemic rats. The number of genes that are significant (adjusted p < 0.05) in the comparison of 4 hyperglycae-
mic GK rats and 4 normoglycaemic BN rats in adipose tissue (477 up; 598 down), liver (95 up; 138 down), and in both tissues 
(41 up; 55 down). Five genes significant in both tissues showed opposite directions of change and are not included in the adi-
pose tissue and liver group.Page 7 of 11
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tion in liver.
Neither of the target gene lists generated by PicTar and
TargetScan, nor the combined list, showed significant
overlap with differentially expressed genes (Table 1). This
was because the overlap between differentially expressed
genes and miR-125a targets occurred largely for genes
uniquely predicted by miRanda. Furthermore, the PicTar
and TargetScan lists are more similar to each other than to
the miRanda list, and so the combined list is biased
toward the genes predicted by these algorithms [Addi-
tional file 3]. It should be noted that it is not the greater
number of targets predicted by miRanda that produces the
significant result, as the size of the target gene list is
accounted for in the analysis.
Discussion
The role of altered miRNA expression in a variety of dis-
eases is increasingly being recognized but the precise
nature and downstream effects of such changes is largely
unknown. Previous studies have shown that miRNAs reg-
ulate various physiological events relevant to T2D patho-
physiology, such as insulin secretion, insulin
responsiveness and energy homeostasis. Here, we have
characterized differential miRNA and mRNA expression
in insulin sensitive tissues of rats of a model of T2D (GK
rat) and in normoglycaemic BN controls, a strain combi-
nation extensively used to study the genetic determinants
of T2D phenotypes in F2 hybrids and congenic strains
[21]. In the miRNA data, the most striking finding was the
over-expression of miR-125a in both liver and adipose tis-
sue (with nearly 6-fold and 2-fold higher expression,
respectively) in GK compared to BN rats. This finding was
validated by RT-PCR in liver (FC = 13.15, p = 0.0005). The
higher sensitivity and dynamic range of the RT-PCR tech-
Table 3: Functional profiling of differentially expressed genes in GK compared to BN rats in adipose tissue (n = 1075) and liver (n = 233) 
using GENECODIS.
KEGG pathway(s) Number of genes Corrected p-value
Adipose tissue
Prostaglandin and leukotriene metabolism 10 0.001
Focal adhesion | ECM-receptor interaction | Hematopoietic cell lineage | Regulation of actin 
cytoskeleton
4 0.002
ECM-receptor interaction | Hematopoietic cell lineage 5 0.002
ECM-receptor interaction 11 0.002
Glycolysis/Gluconeogenesis 9 0.003
Focal adhesion | ECM-receptor interaction 9 0.003
Arginine and proline metabolism 8 0.005
Glycolysis/Gluconeogenesis | Fructose and mannose metabolism 4 0.005
Glycolysis/Gluconeogenesis | Pentose phosphate pathway | Fructose and mannose metabolism 3 0.012
Hematopoietic cell lineage 9 0.015
Cell Communication | Focal adhesion | ECM-receptor interaction 6 0.019
Fructose and mannose metabolism 6 0.019
Porphyrin and chlorophyll metabolism 5 0.029
Folate biosynthesis 5 0.031
Metabolism of xenobiotics by cytochrome P450 7 0.033
Cytokine-cytokine receptor interaction | Focal adhesion 3 0.033
Focal adhesion 14 0.033
Valine, leucine and isoleucine degradation 6 0.033
Cholera – Infection 5 0.033
Fructose and mannose metabolism | Galactose metabolism 3 0.033
Urea cycle and metabolism of amino groups 4 0.033
Glycine, serine and threonine metabolism 5 0.044
Liver
Arginine and proline metabolism 7 2.17E-06
Alanine and aspartate metabolism | Arginine and proline metabolism 3 2.09E-05
Alanine and aspartate metabolism 4 1.30E-04
Urea cycle and metabolism of amino groups | Arginine and proline metabolism 3 0.0017
Prostaglandin and leukotriene metabolism 4 0.0019
Valine, leucine and isoleucine degradation | Butanoate metabolism 3 0.0030
Fatty acid metabolism 3 0.0103
ECM-receptor interaction 3 0.0361Page 8 of 11
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higher than detected by microarray.
MiR-125a and its close homolog miR-125b differ by a sin-
gle nucleotide [40], and thus share many predicted target
genes. Experimentally validated target genes of both miR-
125a and miR-125b in humans include ERBB2 and
ERBB3 [41] and LIN28 [42]. Both miR-125a and miR-
125b have been reported to be down-regulated in ovarian
[43] and breast cancers [44], with potential roles in cell
proliferation and differentiation. To further investigate
the potential role of miR-125a in T2D, we assessed the
functional roles of predicted miR-125a target genes. This
analysis suggested that increased miR-125a levels may
particularly affect genes involved in the MAPK signalling
pathway. MAPK has been implicated in T2D [28,30] and
plays a critical role in insulin signalling [45], and may
contribute to insulin resistance [46]. Further functional
experiments will help elucidate the role of MAPK signal-
ling in T2D and to what extent increased miR-125a
expression may affect this pathway.
We integrated our miRNA results with gene expression
data from the same animals and found an enrichment of
miR-125a target genes predicted by the miRanda algo-
rithm [32] among genes down-regulated in GK rats in adi-
pose tissue. Of particular interest, a proposed functional
candidate gene for T2D, Ptges2, is a predicted miR-125a
target gene and was significantly down-regulated in both
tissues. Two other miR-125a target genes of interest in the
context of T2D and obesity are Ppap2c and Sult1a1, both
of which were significantly down-regulated in adipose tis-
sue from the GK rat. In addition; single nucleotide poly-
morphisms (SNPs) in the SULT1A1 region have
previously been associated with increased BMI in humans
[47]. Contrary to expectation, it was surprising to find an
even stronger enrichment among the up-regulated genes.
One possibility is that these are not direct target genes
themselves, but represent changes further downstream of
the miRNA regulation. No enrichment was observed with
the target gene lists predicted by the other two algorithms,
which may be due to differences in the target-gene predic-
tion methods implemented or to the effects of long-term
exposure to hyperglycaemia further affecting the control
of gene expression. These results show that the relation-
ship between miRNAs and gene expression is not a simple
one.
Though the enrichment of miR-125a target genes pre-
dicted by miRanda is an interesting finding, it raises a
number of questions, including why both down and up-
regulated genes should show significant enrichment of
miR-125a target genes, and why stronger enrichment was
observed for the tissue with lower fold induction of miR-
125a. The difficulty of predicting genuine target genes
combined with other influences on gene expression could
provide some explanation. Furthermore, the current data
do not demonstrate whether the expression of any of the
genes is dysregulated as a direct consequence of the
increased miR-125a levels. One approach to identify
genes likely to be regulated by miR-125a is to find those
that show a strong negative correlation between their
expression and miR-125a levels. Unfortunately, the two-
colour experimental design used for the miRNA study
(generating GK v BN expression ratios) combined with
the small sample size precluded such an analysis here.
Integrating miRNA and mRNA data has the potential to
give further insights into miRNA-mediated regulation of
gene expression but is limited to detecting events in which
the target mRNA is degraded. Still, in-silico approaches
will likely be useful for prioritizing target genes for func-
tional validation.
Our results suggest that increased miR-125a expression
may be a characteristic feature of hyperglycaemic GK rats.
However, as this study was carried out in rats with long-
established T2D phenotypes, it remains unclear whether
the observed changes are causative, or reflect adaptation
to prolonged hyperglycaemia. GK and BN rats are also
genetically different strains, and it is therefore possible
that strain differences unrelated to hyperglycaemia could
contribute to the altered expression of miR-125a.
Although in-silico functional profiling of gene expression
data and miR-125a target genes lends some support to the
idea that miR-125a over-expression is linked to the hyper-
glycaemic phenotype, further evidence from other model
systems or functional studies is certainly desirable.
Among the other miRNAs showing robust differences
between GK and BN rats was a 1.5 fold up-regulation of
miR-29a in adipose tissue. This is exactly comparable with
the only previous study of miRNAs in T2D, which identi-
fied a 1.5 fold up-regulation of miR-29a, together with the
paralogs 29b and 29c, in skeletal muscle from GK and
Wistar rats (normoglycaemic controls)[19]. Northern blot
analysis confirmed the up-regulation of all three miR-29
paralogs in muscle, adipose tissue and liver. This study
further showed that high glucose and insulin (which indi-
cate insulin resistance) up-regulate the expression of miR-
29a/b in adipocyte cell lines. They also suggest the over-
expression of miR-29a/b inhibits insulin-induced glucose
import in the same adipocyte cell lines. Taken together,
these data support the involvement of miR-29a in insulin
resistance and the insulin-signaling pathway.
Conclusion
We have shown that miR-125a expression is increased in
two insulin target tissues in a rat model of T2D. Gene
expression analysis in the same animals revealed a distinct
profile characterizing the hyperglycaemic GK rat, includ-Page 9 of 11
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genes. In-silico functional profiling of predicted miR-125a
targets and differentially expressed genes indicated that
lipid metabolism pathways and MAPK signaling may be
dysregulated in the hyperglycaemic state. Knowledge of
miRNA differential expression between GK and BN rats
provides important information which may contribute to
the understanding of processes which underlie the T2D
phenotype in GK rats through investigations in crosses
and congenic models derived in this strain combination
[48-50]. Further studies at the protein level and transla-
tion across species, especially to humans, will be impor-
tant to elucidate the potential role of miR-125a in T2D
pathophysiology.
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